Loading
A phase 3 trial of Durvalumab, Tremelimumab, Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer is a phase 3 interventional study registered as NCT03682068 by AstraZeneca, with 1246 participants enrolled, started 2018-09-27 and due to reach its primary completion in 2026-06-01. Interventions recorded: Durvalumab, Tremelimumab, Cisplatin + Gemcitabine and Carboplatin + Gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tremelimumab, Muscle-invasive and advanced bladder cancer, Durvalumab, Gemcitabine and the tag pipeline.
Shares Tremelimumab, Muscle-invasive and advanced bladder cancer, Durvalumab, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, AstraZeneca, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Tremelimumab, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/